MiMedx Group, Inc.

MDXG • Biotechnology

$4.57

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$675.43M

Crecimiento

—

Flujo de caja

3/5

Tendencia

Mostly stable

Evidencia

Márgenes estables o en mejora · 11.6%Crecimiento positivo de ingresos · 6.6%Flujo de caja libre positivo · 0.49Múltiplo de ganancias razonable · 20.6Nivel de deuda manejable · 0.09

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$4.57

Change0.00%

Shares Out147.80M

Market Cap$675.43M

Enterprise Value$541.09M

52W Range3.03 - 7.97

Beta1.45

P/E108.29

P/S1.90

P/B3.13

P/FCF14.52

EV/Sales1.52

Price$4.57

Change0.00%

Shares Out147.80M

Market Cap$675.43M

Enterprise Value$541.09M

52W Range3.03 - 7.97

Beta1.45

P/E108.29

P/S1.90

P/B3.13

P/FCF14.52

EV/Sales1.52

EV/EBITDA24.41

EV/FCF11.63

Earnings Yield0.92%

FCF Yield6.89%

Dividend Yield0.00%

Gross Margin82.56%

Oper. Margin15.26%

Profit Margin11.60%

Debt/Eq0.09

Current Ratio4.32

Quick Ratio3.92

Target$7.67

Target Upside67.83%

Target Median$8.00

Target Range7.00 - 8.00

Volume5.97M

Avg Volume1.36M

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

75/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

87/100

Atractivo del precio

Barata o cara hoy

77/100

Por qué este puntaje▼

Márgenes estables o en mejora · 11.6%Crecimiento positivo de ingresos · 6.6%Flujo de caja libre positivo · 0.49Múltiplo de ganancias razonable · 20.6Nivel de deuda manejable · 0.09Liquidez saludable · 4.32

Analyst view

Analyst sentiment and price target

MDXG

Analyst sentiment

Based on 15 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$7.00

Promedio

$8.50

Mediana

$8.50

Alto

$10.00

Resumen de la compañía

IPO: 2/12/2008

Industria: Biotechnology

P/B i: 3.13

Deuda / Patrimonio i: 0.09

Margen operativo: 15.26%

Margen neto: 11.60%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.09

Ratio corriente: 4.32

Ratio rápido: 3.92

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

DOUG RICE

Transacción: 07/02/2026

VENTA

Cambio

-12,749

Precio

$3.95

Presentación

07/07/2026

Tipo

VENTA

Maersk-Moller Kimberly

Transacción: 06/24/2026

VENTA

Cambio

-19,820

Precio

$3.83

Presentación

06/25/2026

Tipo

VENTA

Olson Tiffany

Transacción: 06/10/2026

COMPRA

Cambio

+50,913

Precio

$3.64

Presentación

06/12/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
DOUG RICE	VENTA	-12,749	$3.95	07/02/2026	07/07/2026
Maersk-Moller Kimberly	VENTA	-19,820	$3.83	06/24/2026	06/25/2026
Olson Tiffany	COMPRA	+50,913	$3.64	06/10/2026	06/12/2026
HAWKINS WILLIAM A	COMPRA	+50,913	$3.64	06/10/2026	06/12/2026
Newton Todd	COMPRA	+50,913	$3.64	06/10/2026	06/12/2026
PUHY DOROTHY E	COMPRA	+50,913	$3.64	06/10/2026	06/12/2026
BIERMAN JAMES L	COMPRA	+50,913	$3.64	06/10/2026	06/12/2026
Maersk-Moller Kimberly	VENTA	-6,762	$4.38	03/13/2026	03/17/2026
Hulse William Frank IV	VENTA	-20,245	$4.38	03/13/2026	03/17/2026
DOUG RICE	VENTA	-96,363	$4.50	03/10/2026	03/12/2026
Hulse William Frank IV	VENTA	-61,460	$4.50	03/10/2026	03/12/2026
Maersk-Moller Kimberly	VENTA	-21,270	$4.50	03/10/2026	03/12/2026
Maersk-Moller Kimberly	COMPRA	+62,068	$5.10	03/04/2026	03/06/2026
Maersk-Moller Kimberly	COMPRA	+74,163	Not reported	03/04/2026	03/06/2026
Whitlow Ricci S	COMPRA	+62,068	$5.10	03/04/2026	03/06/2026
Whitlow Ricci S	COMPRA	+74,163	Not reported	03/04/2026	03/06/2026
Hulse William Frank IV	COMPRA	+62,758	$5.10	03/04/2026	03/06/2026
Hulse William Frank IV	COMPRA	+74,987	Not reported	03/04/2026	03/06/2026
DOUG RICE	COMPRA	+62,068	$5.10	03/04/2026	03/06/2026
DOUG RICE	COMPRA	+74,163	Not reported	03/04/2026	03/06/2026

Sobre la compañía

MiMedx Group, Inc.

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

Fuente - Link

Competidores

ATAI CVAC DNTH INBX INVA NKTR RAPP SANA SNDX TSHA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Deutsche Bank AG Takes $520,000 Position in MiMedx Group, Inc $MDXG

Deutsche Bank AG bought a new position in shares of MiMedx Group, Inc (NASDAQ: MDXG) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 135,153 shares of the company's stock, valued at approximately $520,000. Deutsche Bank AG owned about

Defense World

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this c.

Business Wire

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

Seeking Alpha

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.

MarketBeat

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-29	-0.07	-0.05	0.02
2026-02-25	0.09	0.14	0.05
2025-10-29	0.07	0.15	0.08
2025-07-30	0.06	0.1	0.04
2025-04-30	0.06	0.06	0
2025-02-26	0.07	0.07	0
2024-10-30	0.044	0.05	0.006
2024-07-31	0.08	0.08	0
2024-04-30	0.05	0.07	0.02
2024-02-28	0.08	0.04	-0.04
2023-10-30	0.05	0.06	0.01
2023-08-01	0.00518	0.01036	0.00518